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ABSTRACT Coxiella burnetii is an obligate intracellular bacterium and the etiological
agent of Q fever. Successful host cell infection requires the Coxiella type IVB secre-
tion system (T4BSS), which translocates bacterial effector proteins across the vacuole
membrane into the host cytoplasm, where they manipulate a variety of cell pro-
cesses. To identify host cell targets of Coxiella T4BSS effector proteins, we deter-
mined the transcriptome of murine alveolar macrophages infected with a Coxiella
T4BSS effector mutant. We identiﬁed a set of inﬂammatory genes that are signiﬁ-
cantly upregulated in T4BSS mutant-infected cells compared to mock-infected cells
or cells infected with wild-type (WT) bacteria, suggesting that Coxiella T4BSS effector
proteins downregulate the expression of these genes. In addition, the interleukin-17
(IL-17) signaling pathway was identiﬁed as one of the top pathways affected by the
bacteria. While previous studies demonstrated that IL-17 plays a protective role
against several pathogens, the role of IL-17 during Coxiella infection is unknown. We
found that IL-17 kills intracellular Coxiella in a dose-dependent manner, with the
T4BSS mutant exhibiting signiﬁcantly more sensitivity to IL-17 than WT bacteria. In
addition, quantitative PCR conﬁrmed the increased expression of IL-17 downstream
signaling genes in T4BSS mutant-infected cells compared to WT- or mock-infected
cells, including the proinﬂammatory cytokine genes Il1a, Il1b, and Tnfa, the chemo-
kine genes Cxcl2 and Ccl5, and the antimicrobial protein gene Lcn2. We further con-
ﬁrmed that the Coxiella T4BSS downregulates macrophage CXCL2/macrophage in-
ﬂammatory protein 2 and CCL5/RANTES protein levels following IL-17 stimulation.
Together, these data suggest that Coxiella downregulates IL-17 signaling in a T4BSS-
dependent manner in order to escape the macrophage immune response.
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The intracellular bacterium Coxiella burnetii is the etiological agent of Q fever, azoonotic infectious disease. Initially, Q fever manifests as an acute self-limited
ﬂu-like illness. However, patients can develop chronic disease that can be life threat-
ening due to serious clinical manifestations, such as endocarditis (1). Furthermore, the
current therapy recommended for chronic Q fever requires at least 18 months of
doxycycline and hydroxychloroquine treatment (2). An effective vaccine (Q-Vax) has
been developed for humans but is currently licensed only in Australia due to adverse
effects, especially when administered to previously infected populations (3). In addition,
Q fever outbreaks have occurred in several countries, including the Netherlands (4), the
United States (5), Spain (6), Australia (7), Japan (8), and Israel (9), exemplifying how
expansive C. burnetii infection is worldwide and the need for novel therapeutic targets.
Human infection occurs primarily by inhaling contaminated dust or aerosols, often
from close contact with livestock. In the lungs, C. burnetii displays tropism for alveolar
macrophages, where it forms a phagolysosome-like parasitophorous vacuole (PV)
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necessary to support bacterial growth (10, 11). C. burnetii’s ability to survive and
replicate inside the PV, an inhospitable environment for most bacteria, is a unique
feature essential for C. burnetii pathogenesis. C. burnetii exploits the acidic PV pH for
metabolic activation (12) and actively manipulates PV fusogenicity and maintenance
(13). PV establishment requires the translocation of bacterial proteins into the host cell
cytoplasm by the C. burnetii Dot/Icm (defect in organelle trafﬁcking/intracellular mul-
tiplication) type IVB secretion system (T4BSS), closely related to the Dot/Icm T4BSS of
Legionella pneumophila (14). T4BSS effector proteins manipulate not only host vesicular
trafﬁcking during PV development but also other cellular processes, such as lipid
metabolism, host gene expression, apoptosis, host translation, iron transport, ubiquiti-
nation, autophagy, and immunity (15, 16). Based on in silico prediction, there are more
than 100 putative C. burnetii T4BSS effector proteins (17–19), but functional data are
lacking for the majority of these proteins. In particular, the role of T4BSS effector
proteins in manipulating the innate immune response is poorly understood. Recently,
the C. burnetii T4BSS effector protein IcaA was found to inhibit caspase 11-mediated,
noncanonical activation of the nucleotide binding domain and the leucine-rich repeat-
containing protein (NLRP3) inﬂammasome during C. burnetii infection (20). Since
cytosolic lipopolysaccharide (LPS) is known to activate noncanonical inﬂammasomes
(21, 22), it is possible that C. burnetii LPS triggers this pathway and that the bacterium
utilizes T4BSS effectors, such as IcaA, to block this innate immune response. Given the
low infectious dose (10 organisms) (23), C. burnetii certainly inhibits several immedi-
ate host cell responses in order to establish infection.
In order to identify new immune response pathways manipulated by C. burnetii
T4BSS effector proteins, we compared the transcriptome of alveolar macrophages
infected with wild-type (WT) or T4BSS mutant C. burnetii. We identiﬁed a set of
inﬂammatory genes downregulated by C. burnetii T4BSS effector proteins, with the
interleukin-17 (IL-17) signaling pathway being one of the top targeted host cell
pathways. As IL-17 is a proinﬂammatory cytokine that plays a role in the protective
response against a variety of bacterial infections, including those caused by the
pulmonary intracellular pathogens Mycoplasma pneumonia, Mycobacterium tuberculo-
sis, Francisella tularensis, and Legionella pneumophila (24–27), we further investigated
the role of IL-17 during C. burnetii infection. Our data revealed that stimulation of the
macrophage IL-17 signaling pathway leads to C. burnetii killing in a dose-dependent
manner, with the T4BSS mutant displaying increased sensitivity compared to WT
bacteria. Finally, our ﬁndings demonstrate that C. burnetii downregulates the IL-17
signaling pathway in macrophages through T4BSS effector proteins.
RESULTS
Differentially expressed genes in C. burnetii-infected macrophages. In order to
identify T4BSS-dependent changes in the expression of host genes, we determined the
whole transcriptome of murine alveolar (MH-S) macrophages infected with either
wild-type (WT) C. burnetii or a C. burnetii mutant lacking icmD, an essential component
of the T4BSS (14). We previously found minimal differences in PV size and bacterial
replication between the WT and a C. burnetii T4BSS mutant during the ﬁrst 48 h of
infection of MH-S macrophages (28). Thus, to avoid changes in host cell gene expres-
sion that could occur due to PV expansion and bacterial replication after 48 h and
because C. burnetii T4BSS effector protein secretion occurs by 4 h postinfection (hpi)
(29), we analyzed gene expression at 24 and 48 hpi. By principal components analysis
(PCA), global transcription in T4BSS mutant-infected cells more closely resembled that
in mock-infected cells than that in WT-infected cells, suggesting that the active T4BSS
in WT bacteria drastically alters the host cell response to C. burnetii infection (Fig. 1A).
The number of differentially expressed genes (DEGs) was determined for each com-
parison at 24 or 48 hpi, using an absolute fold change threshold of 1.5 and false
discovery rate (FDR) of 5% (see Data Set S1 in the supplemental material). The largest
differences in gene expression at 24 hpi and 48 hpi were between icmD mutant-
infected cells versus WT-infected cells (110 DEGs at 24 hpi) and WT-infected cells versus
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FIG 1 C. burnetii infection alters the gene expression proﬁle of alveolar macrophages in a T4BSS-dependent manner. The transcriptomes of
MH-S macrophages infected with wild-type (WT) or icmD T4SS mutant C. burnetii were analyzed at 24 or 48 hpi. (A) Principal components
(Continued on next page)
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mock-infected cells (116 DEGs at 48 hpi), respectively (Fig. 1B; Data Set S1). Unsuper-
vised hierarchical cluster analysis of fold change values for DEGs (absolute log2 fold
change, 0.585; FDR, 5%) across all six possible two-way comparisons revealed that
the majority of DEGs were upregulated in icmDmutant-infected cells compared to their
expression in WT-infected cells (Fig. 1C, icmD versus WT). In contrast, the majority of
DEGs were downregulated in WT-infected versus mock-infected cells (Fig. 1C, WT versus
mock). Overall, there were fewer downregulated genes in the icmD mutant-infected
cells than in the mock-infected cells (Fig. 1C, icmD versus mock). This provides evidence
that C. burnetii T4BSS effector proteins may play a role in the downregulation of host
cell genes during the initial stages of infection.
To identify the biological pathways targeted by C. burnetii T4BSS effector proteins,
we used two methods: gene set enrichment via CERNO testing (30) using Gene
Ontology (GO) annotations as gene sets (Fig. S1) and Ingenuity Pathways Analysis (IPA)
using DEGs with an absolute log2 fold change of 0.585 and an FDR of 5% as inputs
(Fig. 1D and S2). Both methods revealed differential expression of several immune and
inﬂammatory pathways, including pathogen recognition and activation of the inter-
feron regulatory factor (IRF) by cytosolic pattern recognition receptors (PRRs) and
transmembrane PRRs, signaling pathways induced by the proinﬂammatory cytokines
IL-1 and IL-1, chemokine activity, T cell migration, and nuclear factor B (NF-B)
phosphorylation. In addition, our data indicate that the C. burnetii T4BSS signiﬁcantly
downregulates the macrophage type I interferon (IFN) response. This ﬁnding supports
published data that C. burnetii does not induce a robust type I IFN response in
macrophages (31). In addition, IL-17 signaling was among the top three overrepre-
sented canonical pathways between mutant and WT infection (Fig. 1D), with upstream
regulator analysis predicting activation of IL-17 signaling in icmD mutant-infected cells
relative to mock-infected cells (Fig. S2). Given that IL-17 is known to be an important
proinﬂammatory cytokine against several pulmonary pathogens, we speciﬁcally tested
for the differential expression of IL-17-related genes (32) using self-contained gene set
testing. The IL-17 gene set was overexpressed in icmD mutant-infected macrophages
relative to WT-infected macrophages (Table S1), suggesting that the C. burnetii T4BSS
downregulates IL-17 signaling in macrophages.
To validate the transcriptome analysis, we used quantitative reverse transcription-
PCR (qRT-PCR) of infected macrophages to test the expression of the IL-17 pathway and
other proinﬂammatory genes. RNA was isolated from MH-S macrophages infected with
either WT C. burnetii or a C. burnetii mutant lacking dotA, another essential component
of the T4BSS (33). Like the icmD mutant, the dotA mutant does not translocate T4BSS
effector proteins, allowing us to conﬁrm that gene expression changes are indeed
T4BSS dependent. Lipopolysaccharide (LPS), a potent stimulator of the inﬂammatory
response (34), served as a positive control. Between the WT- and dotA mutant-infected
macrophages, we observed a signiﬁcant difference in expression of the proinﬂamma-
tory genes Il1a, Il1b, and Tnfa (Fig. 2A to C), as well as the IL-17 signaling pathway
chemokines Cxcl2/Mip2 and Ccl5/Rantes (Fig. 2D and E) and the antimicrobial protein
Lipocalin-2 (Lcn2) (Fig. 2F). These genes were upregulated in the dotA mutant-infected
macrophages compared to WT-infected macrophages, with more signiﬁcant differ-
ences being found at 24 hpi than at 48 hpi. The gene for IL-17A itself was not
differentially regulated in either our RNA sequencing (RNA-seq) data or qRT-PCR data
FIG 1 Legend (Continued)
analysis (PCA) of genome-wide expression across all RNA-seq samples after normalization of raw data. (B) Venn diagram of differentially
expressed genes for each comparison for each time point using an absolute log2 fold change (logFC) of 0.585 (1.5-fold in linear space) and
a false discovery rate (FDR) of0.05. (C) Unsupervised hierarchical clustering heat map of log2 fold change values for all six comparisons using
the ward.D2 clustering method and Euclidean distance. Red intensity indicates increased expression in the ﬁrst group relative to that in the
second group, whereas blue intensity indicates decreased expression. (D) Ingenuity Pathway Analysis (IPA) using differentially expressed
genes for the comparison between WT-infected cells and icmD mutant-infected cells at 24 hpi. Red shading indicates increased pathway
activity in icmD mutant-infected cells, whereas blue shading indicates increased pathway activity in WT-infected cells, based on IPA activity
Z-scores. White shading indicates that no activity pattern was predicted or could be determined. TNFR2, tumor necrosis factor receptor 2;
PPAR, peroxisome proliferator-activated receptor; PI3K, phosphatidylinositol 3-kinase; MIF, migration inhibition factor; PKR, protein kinase R.
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(data not shown), which is not surprising, given that macrophages produce very little
IL-17 (35). These data suggest that, during the early stages of macrophage infection, the
C. burnetii T4BSS may target the IL-17 pathway in order to downregulate expression of
several proinﬂammatory genes.
C. burnetii downregulates CXCL2/MIP-2 and CCL5/RANTES expression in a
T4BSS-dependent manner. A number of studies have shown that IL-17 plays an
important role in the innate immune response against bacteria by stimulating secretion
of multiple chemokines. Within the context of infection, these chemokines recruit
macrophages, neutrophils, and lymphocytes to the infection site, thereby enhancing
inﬂammation. To validate the gene expression changes between macrophages infected
with the WT or the T4BSS mutant, we measured the secretion of CXCL2/macrophage
inﬂammatory protein 2 (MIP-2) and CCL5/RANTES at 24 or 48 hpi using an enzyme-
linked immunosorbent assay (ELISA). We observed a signiﬁcant difference in CXCL2/
MIP-2 and CCL5/RANTES protein levels between the WT- and dotA mutant-infected
macrophages, with a 3-fold increase of both cytokines in the dotA mutant-infected
macrophages (Fig. 3A and B), conﬁrming the gene expression data. While the CXCL2/
MIP-2 level was signiﬁcantly higher at both 24 and 48 hpi, we detected a difference in
CCL5/RANTES expression only at 24 hpi (Fig. 3B).
LCN2 expression is strongly induced by IL-17 and blocks catecholate-type sidero-
phores of Gram-negative bacteria, preventing the bacteria from scavenging the free
FIG 2 C. burnetii T4BSS effector proteins downregulate expression of the IL-17 pathway. Quantitative RT-PCR gene expression analysis of IL-17
pathway genes in macrophages infected with wild-type (WT) or dotA mutant C. burnetii at 24 or 48 hpi. Mock-infected macrophages treated with
LPS (100 ng/ml) for 24 h were used as a positive control. The expression of individual genes was normalized to that of Gapdh, and the fold change
in expression over that in mock-infected cells was determined. Compared to their levels of expression in WT-infected cells, macrophages infected
with dotA mutant C. burnetii had higher levels of expression of the IL-17 pathway genes IL1a (A), IL1b (B), Tnfa (C), Cxcl2 (D), Ccl5 (E), and Lcn2
(F). Error bars show the average  SEM from three independent experiments, performed in biological duplicate with three technical replicates.
P values were determined by one-way ANOVA with Tukey’s post hoc test and represent statistically signiﬁcant differences compared to
mock-infected cells or between WT and dotA mutant-infected cells. *, P  0.05; **, P  0.01; ***, P  0.005; ****, P  0.001.
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iron required for bacterial growth (36, 37). While Lcn2 gene expression was differentially
regulated (Fig. 2F), we did not observe a signiﬁcant difference in secreted LCN2 protein
levels between the WT- and dotA mutant-infected macrophages at either 24 or 48 hpi
(Fig. 3C). These conﬂicting data may be due to the posttranslational regulation of LCN2
(38). However, our data do suggest that the C. burnetii T4BSS downregulates macro-
phage secretion of the chemokines CXCL2/MIP-2 and CCL5/RANTES during infection.
C. burnetii T4BSS effector proteins impair IL-17-stimulated CXCL2/MIP-2 and
CCL5/RANTES secretion. The chemoattractant CXCL2/MIP-2 is typically secreted by
monocytes and macrophages and recruits neutrophils that are required for pathogen
clearance (39). Furthermore, CCL5/RANTES, which is secreted by lymphocytes, macro-
phages, and endothelial cells, also recruits and activates leukocytes (40). We ﬁrst
conﬁrmed that IL-17 upregulates CXCL2/MIP-2 and CCL5/RANTES in MH-S alveolar
macrophages by treating uninfected macrophages with recombinant mouse IL-17A
and analyzing the cell-free supernatant by ELISA. In uninfected macrophages, the levels
of CXCL2/MIP-2 and CCL5/RANTES increased 14-fold and 2-fold, respectively, following
IL-17A treatment for 24 h (Fig. 4A and B). To test if C. burnetii T4BSS effector proteins
FIG 3 The C. burnetii T4BSS decreases the secretion of CXCL2/MIP-2 and CCL5/RANTES in infected MH-S
macrophages. ELISA quantitation of the CXCL2/MIP-2, CCL5/RANTES, and Lipocalin-2 (LCN2) proteins in
the supernatant of macrophages infected with WT or dotAmutant C. burnetii at 24 or 48 hpi. Cells treated
with LPS (100 ng/ml) were used as a positive control. Compared to the levels of secretion in mock-
infected and WT-infected macrophages at 24 hpi, dotA mutant-infected macrophages had increased
secretion of CXCL2/MIP-2 (A) and CCL5/RANTES (B) but not LCN2 (C). Shown are the means  SEM from
three independent experiments done in duplicate. P values were determined by one-way ANOVA with
Tukey’s post hoc test. *, P  0.05; **, P  0.01; ***, P  0.005; ****, P  0.001.
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block IL-17-stimulated chemokine secretion, WT- or dotAmutant-infected macrophages
were treated with IL-17A for 24 h. In IL-17-stimulated macrophages infected with WT
bacteria, CXCL2/MIP-2 levels decreased 2.2-fold compared to those in stimulated
mock-infected macrophages, while CCL5/RANTES levels decreased 1.6-fold (Fig. 4A and
B), suggesting that WT C. burnetii blocks IL-17-induced chemokine secretion. Further,
dotAmutant C. burnetii did not block IL-17A-stimulated CXCL2/MIP-2 and CCL5/RANTES
(Fig. 4A and B). These data suggest that the C. burnetii T4BSS impairs IL-17 signaling in
macrophages, including secretion of CXCL2/MIP-2 and CCL5/RANTES.
Triggering the macrophage IL-17 pathway is bactericidal. Several studies have
demonstrated that IL-17 plays a protective role for the host during bacterial infections
(32, 41–43). To evaluate if IL-17 affects C. burnetii viability in macrophages, we treated
infected macrophages at 24 or 48 hpi with recombinant mouse IL-17A and enumerated
the viable bacteria 24 h later using a ﬂuorescent infectious focus-forming unit (FFU)
assay in Vero cells (44). IL-17 stimulation decreased C. burnetii viability at 24 and 48 hpi
in a dose-dependent manner, with an 40% decrease being found at the highest
concentration (Fig. S3). IL-17A treatment did not affect macrophage viability (data not
shown). Interestingly, C. burnetii appeared to be more resistant to IL-17 stimulation at
48 hpi than at 24 hpi, as low concentrations of IL-17 (50 ng/ml) led to a signiﬁcant loss
of bacterial viability only at 24 hpi (Fig. S3A and B). To determine if the T4BSS is related
to bacterial susceptibility to IL-17, we infected macrophages with either WT or dotA
mutant C. burnetii, stimulated with IL-17A, and measured bacterial viability by a CFU
assay on agarose plates (45). We observed a stronger bactericidal effect of IL-17 on dotA
mutant C. burnetii than on WT C. burnetii, as the presence of 25 and 12.5 ng/ml of IL-17
led to a 47% and 39% loss of dotA mutant C. burnetii viability, respectively, but did not
affect WT C. burnetii viability (Fig. 5A and S4). To further assess the speciﬁcity of IL-17
FIG 4 C. burnetii T4BSS blocks IL-17-stimulated secretion of CXCL2/MIP-2 and CCL5/RANTES. The results
of ELISA quantitation of CXCL2/MIP-2 (A) and CCL5/RANTES (B) protein levels after IL-17A (100 ng/ml)
treatment of mock-infected, WT-infected, or dotAmutant-infected macrophages at 24 hpi are shown. The
means  SEM from three individual experiments performed in duplicate are shown. P values were
determined by one-way ANOVA with Tukey’s post hoc test and represent statistically signiﬁcant differ-
ences compared to mock-infected cells or between WT and dotA mutant-infected cells. *, P  0.05; **,
P  0.01; ****, P  0.001.
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activity, we treated infected cells with IL-17 (50 or 100 ng/ml) in the presence or
absence of an antibody that blocks the IL-17 receptor (IL-17R). The IL-17 bactericidal
effect was signiﬁcantly neutralized by blocking the IL-17 receptor, as cotreatment with
IL-17 and the anti-IL-17 receptor antibody rescued over 30% of the bacterial viability
compared to that of IL-17-treated infected cells (Fig. 5B and S4).
In order to validate the bactericidal effect of IL-17 in primary cells, human monocyte-
derived macrophages (hMDMs) were infected with the WT or the C. burnetii dotA
mutant and treated at 24 hpi with recombinant human IL-17A, and bacterial viability
was measured after 24 h by the CFU assay. Conﬁrming our results obtained in MH-S
cells, the dotA T4BSS mutant viability decreased with IL-17 treatment (Fig. 5C and S4),
with a 50% decrease in the number of viable bacteria being seen at 100 ng/ml.
FIG 5 Activating the macrophage IL-17 pathway can kill C. burnetii, but the T4BSS effector proteins play
a protective role. (A and B) MH-S cells were infected for 24 h, followed by treatment for 24 h with either
IL-17 alone (A) or IL-17 and an IL-17A receptor-blocking antibody (2 g/ml) (B). (C) hMDMs were infected
for 24 h and treated with human IL-17A for 24 h. Viable bacteria were quantitated using an agarose-
based CFU assay, and the loss of bacterial viability was calculated by dividing the number of WT or T4SS
mutant bacteria in treated samples by the number in their respective untreated samples (). The dotA
T4BSS mutant is more sensitive to IL-17 than WT bacteria in both MH-S and hMDMs, and the viability of
both WT and dotA mutant C. burnetii could be recovered by blocking IL-17 receptor signaling. Error bars
indicate the mean  SEM from four individual experiments. P values were determined by one-way
ANOVA with Dunnett’s post hoc test and represent statistically signiﬁcant differences compared to the
untreated controls. *, P  0.05; **, P  0.01; ***, P  0.005; ****, P  0.001.
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However, IL-17 had no effect on WT C. burnetii in primary hMDMs. Together, these data
suggest that activation of the IL-17 signaling pathway in macrophages kills intracellular
C. burnetii bacteria, with the C. burnetii T4BSS playing a protective role.
DISCUSSION
The innate immune response relies on pathogen detection by pattern recognition
receptors, which activate signaling pathways and trigger an inﬂammatory response
(46). While the innate immune response is essential to protect the host, pathogens such
as C. burnetii have evolved strategies to overcome the host innate immune response
(47, 48). Despite being sequestered in a growth-permissive vacuole, C. burnetii T4BSS
effector proteins manipulate a variety of host cell signaling processes, including the
innate immune responses of inﬂammasome-mediated pyroptotic and apoptotic cell
death (20, 49–51). To identify potential targets of C. burnetii T4BSS effector proteins, we
compared the transcriptomes of murine alveolar macrophages infected with either WT
or T4BSS mutant C. burnetii. We identiﬁed several inﬂammatory pathways downregu-
lated by C. burnetii T4BSS effector proteins, including IL-17 signaling. Previous studies
demonstrated that IL-17 plays a protective role against several pathogens, including L.
pneumophila, the closest pathogenic relative of C. burnetii (25–27, 41, 42). We found
that C. burnetii downregulates the macrophage IL-17 signaling pathway in a T4BSS-
dependent manner, protecting the bacteria from IL-17-mediated killing by the macro-
phage and blocking the secretion of proinﬂammatory chemokines. To our knowledge,
this is the ﬁrst demonstration of a pathogenic bacterium directly downregulating
intracellular macrophage IL-17 signaling.
Previous studies demonstrated that C. burnetii infection leads to secretion of the
proinﬂammatory cytokines tumor necrosis factor alpha (TNF-) and gamma interferon
(IFN-), with both cytokines playing critical roles in restricting C. burnetii replication
(52–54). In our studies, gene expression analysis during the early stages of infection
revealed striking differences in the immunological response to WT and T4BSS mutant
C. burnetii, with C. burnetii T4BSS mutant-infected macrophages having a stronger
proinﬂammatory response. For example, the proinﬂammatory genes Il1a, Il1b, and Tnfa
are expressed at higher levels in macrophages infected with T4BSS mutant C. burnetii
than in WT-infected macrophages. Bacterium-driven downregulation of these and
other proinﬂammatory cytokines would beneﬁt the bacteria in establishing infection. In
support of our data, C. burnetii infection of primary macrophages does not activate
caspase 1 (20), an enzyme required for the production of the proinﬂammatory cyto-
kines IL-1 and IL-1 (55, 56). Interestingly, C. burnetii does not directly inhibit caspase
1 activation but appears to interfere with upstream signaling events, including blocking
TNF- signaling (20, 57). However, a recent study did not detect signiﬁcant differences
in TNF- production in murine bone marrow-derived macrophages infected with WT C.
burnetii or icmL mutant C. burnetii, a mutant with a nonfunctional T4BSS (31). These
apparently conﬂicting data may be explained by the use of C57BL/6 mice in the latter
study; C57BL/6 mice, in contrast to other inbred mouse strains, are not permissive for
intracellular C. burnetii replication due to the large amount of TNF- produced upon
Toll-like receptor (TLR) stimulation (31, 58–60). Further experimentation is required to
elucidate the mechanism(s) behind C. burnetii T4BSS-mediated downregulation of the
macrophage proinﬂammatory response.
Pathogen-associated molecular patterns (PAMPs) are sensed by different PRRs,
which activate IRFs and initiate key inﬂammatory responses, including the transcription
of type I interferons (IFN) and IFN-inducible genes (61, 62). Type I IFN can be induced
by many intracellular bacterial pathogens either via recognition of bacterial surface
molecules, such as LPS, or through stimulatory ligands released by the bacteria via
specialized bacterial secretion systems (63). Our transcriptome analysis revealed C.
burnetii T4BSS-mediated downregulation of macrophage IRF activation by cytosolic and
transmembrane PRRs. A recent study found that C. burnetii does not trigger cytosolic
PRRs or induce robust type I IFN production in mouse macrophages (31). Additionally,
IFN- receptor-deﬁcient (IFNAR/) mice were protected from C. burnetii infection,
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suggesting that type I IFNs are not required to restrict bacterial replication (31, 64).
However, delivery of recombinant IFN- to the lungs of C. burnetii-infected mice
protected against bacterial replication, revealing a potential role of type I IFN in the
control of C. burnetii infection in the lung (64). Interestingly, type I IFN is induced during
L. pneumophila infection and plays a key role in macrophage defense by restricting
intracellular bacterial replication (65, 66). However, to counteract this host immune
response, the L. pneumophila type IV secretion system (T4SS) effector protein SdhA
suppresses the induction of IFN through an unknown mechanism (67). Similarly, our
data suggest that C. burnetii T4BSS effector proteins negatively modulate the type I IFN
response in alveolar macrophages, most likely as a bacterial immune evasion mecha-
nism.
In addition to proinﬂammatory cytokines and PRRs, we discovered an important role
for the cytokine IL-17 during C. burnetii infection of macrophages. The protective role
of IL-17 against extracellular bacteria has been extensively studied; additionally, IL-17
can be critical for the full immune response leading to the control of intracellular
bacteria (32, 42, 43, 68). IL-17 is produced by T helper 17 (Th17) cells,  T cells, and
invariant natural killer T (iNKT) cells (69). In the lung,  T cells have been implicated as
a primary source of early IL-17 production in several in vivo models of infection (70),
which may have implications for C. burnetii lung infection. Exogenous IL-17 binds the
IL-17 receptor on the surface of the macrophage, triggering chemokine secretion,
neutrophil recruitment, and a Th1 response, thus enhancing bacterial clearance (26, 27,
71, 72). By both gene expression and protein analysis, we found that C. burnetii
downregulates IL-17-stimulated chemokine secretion in macrophages in a T4BSS-
dependent manner. A previous study found that following C. burnetii aerosol infection
in mice, neutrophils are not present in the airways until 7 days postinfection, though
the mechanism of this delay remains unknown (73). Further, neutrophils play a critical
role in inﬂammation and bacterial clearance following intranasal C. burnetii infection,
but it is unknown whether neutrophils directly kill the bacteria or serve to enhance the
immune response (74). Based on our ﬁndings in alveolar macrophages, we hypothesize
that C. burnetii T4BSS effector proteins downregulate the IL-17 pathway to suppress
chemokine secretion as a mechanism to avoid neutrophil recruitment at early stages of
infection. This could be an important immune evasion strategy that enables the
bacteria to establish long-term persistence. In addition to chemokines, the IL-17-
stimulated protein LCN2 may also be downregulated by C. burnetii. LCN2 is a
siderophore-binding antimicrobial protein that can limit bacterial growth by iron
restriction.
A previous study demonstrated that C. burnetii-infected IL-17 receptor knockout
mice had a bacterial burden in the spleen and lung similar to that in infected WT mice,
suggesting that IL-17 does not play an essential role during C. burnetii infection (74). In
contrast, our in vitro studies revealed that activating the IL-17 signaling pathway in
macrophages can directly kill intracellular C. burnetii. Further, the C. burnetii T4BSS
appears to play a protective role, presumably by blocking the intracellular signaling
pathway triggered by IL-17 binding to IL-17R. Our data may explain the lack of
phenotypic changes in IL-17 receptor knockout mice infected by WT C. burnetii, as the
intracellular signaling pathway is not activated in the absence of the IL-17 receptor.
During acute C. burnetii infection in humans, the number of  T cells rises
signiﬁcantly in the peripheral blood of patients (75). Given that  T cells can secrete
large amounts of IL-17 (76), it is possible that the downregulation of intracellular IL-17
signaling by T4BSS effector proteins might be an essential mechanism of immune
evasion that allows C. burnetii persistence. IL-17 activates common downstream path-
ways in macrophages, including the nuclear factor B (NF-B) and mitogen-activated
protein kinase (MAPK) pathways (77, 78). Our transcriptome data suggest that the C.
burnetii T4BSS downregulates the genes involved in the IL-17 canonical NF-B signaling
pathway, including Il17ra, Il17rc, Traf6, Nfkb1, and Nfkb2. This hypothesis is consistent
with a recent study that found that C. burnetii can modulate the NF-B canonical
pathway through the T4BSS (79). NF-B activation correlates with enhanced expression
Clemente et al. Infection and Immunity
October 2018 Volume 86 Issue 10 e00532-18 iai.asm.org 10
of inducible nitric oxide synthase (iNOS) (80) and NADPH oxidase (NOX) (81), which
generate nitric oxide (NO) and reactive oxygen species (ROS), respectively. Both NO and
ROS are signature molecules for M1 macrophages (82), while C. burnetii-infected
macrophages exhibit an M2 polarization that is unable to control bacterial replication
(83). As IL-17 alters macrophage polarization (84), one potential mechanism is that IL-17
polarizes toward the M1 phenotype, triggering ROS and NO, leading to C. burnetii
killing. In addition, as IFN- plays a clear role in C. burnetii killing (53, 54), the IL-17
bactericidal effect might be related to IFN-, as IL-17 can induce an IFN- response (85).
Further experimentation is needed to identify not only the C. burnetii T4BSS effector
protein modulating IL-17 signaling in macrophages but also how IL-17 leads to C.
burnetii death inside macrophages.
In summary, this study suggests that C. burnetii employs the T4BSS to downregulate
IL-17 signaling in macrophages during the early stages of infection. This has important
implications in both controlling the proinﬂammatory response elicited by the macro-
phages and avoiding direct killing by the macrophage. Further studies identifying the
bacterial T4BSS effector proteins involved in this mechanism and elucidating how IL-17
kills C. burnetii will give new insight into immune evasion by C. burnetii.
MATERIALS AND METHODS
Bacteria and mammalian cells. Coxiella burnetii Nine Mile phase II (NMII; clone 4, RSA439) was
puriﬁed from Vero cells (African green monkey kidney epithelial cells; CCL-81; American Type Culture
Collection, Manassas, VA) and stored as previously described (86). For all experiments, the C. burnetii NMII
wild type (WT), icmDmutant (14), and dotAmutant (33) were grown for 4 days in acidiﬁed citrate cysteine
medium 2 (ACCM-2) at 37°C in 2.5% O2 and 5% CO2, washed twice with phosphate-buffered saline (PBS),
and stored as previously described (87). Murine alveolar (MH-S) macrophages (CRL-2019; ATCC) were
maintained in growth medium consisting of RPMI 1640 medium (Corning, New York, NY, USA) containing
10% fetal bovine serum (FBS; Atlanta Biologicals, Norcross, GA, USA) at 37°C in 5% CO2. The multiplicity
of infection (MOI) for each bacterial stock was optimized for each bacterial stock and culture vessel for
a ﬁnal infection of approximately 1 internalized bacterium per cell. To obtain human monocyte-derived
macrophages (hMDMs), peripheral blood mononuclear cells were isolated from buffy coats (Indiana
Blood Center) using Ficoll-Paque (catalog number 17144002; GE Healthcare). Monocytes were isolated
from lymphocytes by positive selection using CD14 magnetic beads (catalog number 11367D; Dyna-
beads FlowComp human CD14; Thermo Fisher Scientiﬁc). Following isolation, monocytes were cultured
for 7 days with RPMI 1640 medium containing 10% FBS, 100 mg/ml penicillin-streptomycin, and 50 ng/ml
human macrophage colony-stimulating factor (M-CSF; catalog number 14-8789-62; Thermo Fisher
Scientiﬁc). At 24 h prior to infection, the medium containing antibiotics and M-CSF was replaced with
RPMI 1640 medium containing 10% FBS.
RNA sequencing. MH-S cells (4  105 cells per well of a 6-well plate) were mock infected or infected
with WT or icmD mutant C. burnetii, with three replicates being used per condition. Total RNA was
isolated at 24 and 48 hpi using an RNeasy Plus minikit (Qiagen). RNA samples had an RNA integrity
number of 7, as determined on an Agilent 2100 bioanalyzer. RNA-seq libraries were prepared using a
ScriptSeq Complete kit (Illumina, Inc.) according to the manufacturer’s instructions. Libraries were
sequenced at 30 million reads per sample on an Illumina NextSeq platform with read lengths of 75 bp
by the Indiana University Bloomington Center for Genomics and Bioinformatics and mapped to the
mouse reference genome mm10 by the Indiana University Center for Computational Biology and
Bioinformatics. RNA processing and sequencing were performed as a single batch. The median library
size (mapped reads) was 17.8 million reads, with the minimum being 13.4 million reads.
Gene expression analysis. RNA-seq differential gene expression (DGE) analysis was performed using
the edgeR package (version 3.16.5) in R (version 3.3.3). After ﬁltering genes with low levels of expression
across a majority of samples, trimmed mean of M (TMM) value normalization was applied to the
remaining 9,400 genes. Expression data for these genes were converted to log counts per million
(logCPM) for data visualization with principal components analysis (PCA) plots. DGE analysis was
performed using the glmLRT function as 2-way comparisons between the three classes using the
following model matrix formula: 0  Infection_Time, where Infection_Time is a combined factor
variable consisting of cell treatment and time point (six levels). The fold change in gene expression was
determined by comparing wild-type- or icmD mutant-infected cells to mock-infected cells or each other
at either 24 h or 48 h (six different comparisons). Differential expression of functional pathways was
assessed by two methods using the list of differentially expressed genes (DEGs) for each comparison: (i)
gene enrichment analysis using CERNO testing in the tmod package (version 0.31) (30) in R with Gene
Ontology (GO; C5 in MSigDB [88]) annotations as gene sets and all DEGs without cutoff criteria but
ranked by ascending P values and (ii) Ingenuity Pathways Analysis (version 42012434) using DEGs with
a 	log2 fold change	 of 0.585 (1.5 in linear space) and an FDR of 5% as inputs. In addition,
self-contained gene set testing for enrichment of IL-17-related genes (32) was also performed using the
roast.DGElist function in the edgeR package and the following gene list: Ccl5, Il17rc, Lcn2, Traf6, Il17ra,
Nfkb1, Nfkb2, Ccl2, and Ccl3.
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Quantitative gene expression by real time-PCR (RT-qPCR). MH-S cells (2  105 cells per well of a
6-well plate) were mock infected or infected with WT or dotAmutant C. burnetii in 0.5 ml growth medium
for 2 h at 37°C in 5% CO2, washed extensively with PBS, and incubated in 2 ml of growth medium. Cells
treated with LPS (100 ng/ml) from Escherichia coli O111:B4 (catalog number L4392; Sigma) were used as
a positive control. RNA was isolated using an RNeasy Plus minikit at 24 and 48 hpi and analyzed for
quantity and the A260/A280 ratio (Implen NanoPhotometer), and cDNA was generated using a SuperScript
III ﬁrst-strand synthesis system kit (Invitrogen). Real-time PCR using a Luminaris Color HiGreen quanti-
tative PCR (qPCR) master mix (Thermo Fisher Scientiﬁc) was done on a Bio-Rad CFX Connect real-time
system according to the manufacturer’s instructions. Mouse-speciﬁc primers (5= to 3=) were as follows: for
Il1b, forward primer TGTAATGAAAGACGGCACACC and reverse primer TCTTCTTTGGGTATTGCTTGG; for
Il1a, forward primer CGCTTGAGTCGGCAAAGAAAT and reverse primer ACAAACTGATCTGTGCAAGTCTC;
for Tnfa, forward primer TTCTGTCTACTGAACTTCGGG and reverse primer GTATGAGATAGCAAATCGGCT;
for CCL5/RANTES, forward primer ACTCCCTGCTGCTTTGCCTAC and reverse primer ACTTGCTGGTGTAGA
AATACT; for CXCL2/MIP-2, forward primer CGCTGTCAATGCCTGAAGAC and reverse primer ACACTCAAG
CTCTGGATGTTCTTG; for Lcn2, forward primer TTTCACCCGCTTTGCCAAGT and reverse primer GTCTCTG
CGCATCCCAGTCA; and for Gapdh (glyceraldehyde-3-phosphate dehydrogenase), forward primer AAGG
TCATCCCAGAGCTGAA and reverse primer CTGCTTCACCACCTTCTTGA. The relative levels of transcripts
were calculated by the ΔΔCT threshold cycle (CT) method using Gapdh as the internal control. The relative
levels of mRNA from the mock-infected samples were adjusted to 1 and served as the basal control value.
Each experiment was done in biological duplicate, and qPCR was performed on three separate cDNA
preparations from each RNA.
ELISA. CXCL2-MIP-2, CCL5-RANTES, and Lipocalin-2 protein levels in cell-free supernatants were
measured by ELISA (R&D Systems, Minneapolis, MN) according to the manufacturer’s instructions. In
brief, MH-S cells (5  104 cells per well of a 24-well plate) were plated and allowed to adhere overnight.
The cells were then mock infected or infected with WT or dotA mutant C. burnetii in 0.25 ml growth
medium for 2 h at 37°C in 5% CO2, washed extensively with PBS, and incubated in 0.5 ml growth medium.
To examine the IL-17 pathway expression in infected cells, the cells were pretreated with 100 ng/ml of
IL-17A recombinant mouse protein (catalog number PMC0174; Thermo Fisher Scientiﬁc) for 24 h and
then infected as described above. LPS-treated cells (100 ng/ml; catalog number L4391; Sigma) were used
as a positive control. The cell supernatant was collected at 24 or 48 hpi, centrifuged at 20,000  g for
10 min, and analyzed by ELISA. Each experiment was performed in biological duplicate with two
technical replicates.
C. burnetii viability by ﬂuorescent infectious FFU and CFU assays. MH-S cells (5  104 cells per
well of a 24-well plate) were plated and allowed to adhere overnight, while monocytes (1 105 cells per
well of a 24-well plate) were plated and differentiated to hMDMs for 7 days. The cells were then mock
infected or infected with WT or dotA mutant C. burnetii in 0.25 ml growth medium for 2 h at 37°C in 5%
CO2, washed extensively with PBS, and incubated in 0.5 ml growth medium. At the indicated time points,
the cells were treated with different concentrations of either recombinant mouse IL-17A or recombinant
human IL-17A (catalog number 14-8179-62; Thermo Fisher Scientiﬁc) for 24 h. The cells were lysed in
sterile water for 5 min and analyzed by a focus-forming unit (FFU) assay as previously described (89). For
the CFU assay, the released bacteria were diluted 1:5 in ACCM-2 and plated in 2-fold serial dilutions onto
0.25% ACCM-2 agarose plates (45). The plates were incubated for 7 to 9 days at 37°C in 2.5% O2 and 5%
CO2, and the number of colonies was counted to measure bacterial viability. Each experiment was
performed in biological duplicate, and the bacteria were spotted in triplicate.
Antibody neutralization. MH-S cells (5  104) were mock infected or infected with WT or dotA
mutant C. burnetii in a 24-well plate. At 24 hpi, the cells were treated with 50 or 100 ng/ml of IL-17A
in the presence or absence of 2 g/ml of anti-IL-17Ra monoclonal antibody (catalog number
MAB4481; Thermo Fisher Scientiﬁc) for 24 h. Bacteria were released by water lysis and analyzed by
the CFU assay as described above. Each experiment was performed in biological duplicate, and the
bacteria were spotted in triplicate.
Data analysis. Statistical analyses were performed using ordinary one-way analysis of variance
(ANOVA) with Dunnett’s or Turkey’s multiple-comparison test in Prism (version 7) software (GraphPad
Software, Inc., La Jolla, CA).
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